HRP20140022T1 - Spojevi sulfonamida za lijeäśenje respiratornih poremeä†aja - Google Patents
Spojevi sulfonamida za lijeäśenje respiratornih poremeä†aja Download PDFInfo
- Publication number
- HRP20140022T1 HRP20140022T1 HRP20140022AT HRP20140022T HRP20140022T1 HR P20140022 T1 HRP20140022 T1 HR P20140022T1 HR P20140022A T HRP20140022A T HR P20140022AT HR P20140022 T HRP20140022 T HR P20140022T HR P20140022 T1 HRP20140022 T1 HR P20140022T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- benzenesulfonamide
- yloxy
- pyrazol
- dichloro
- Prior art date
Links
- -1 Sulfonamide compounds Chemical class 0.000 title claims 3
- 208000023504 respiratory system disease Diseases 0.000 title claims 3
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QYZAFPHEJIYKNK-UHFFFAOYSA-N 2,4-dichloro-n-[3,5-dichloro-4-[1-(2,4-difluorophenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound FC1=CC(F)=CC=C1N1N=CC(OC=2C(=CC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)Cl)=CC=2Cl)Cl)=C1 QYZAFPHEJIYKNK-UHFFFAOYSA-N 0.000 claims 1
- SRTYGDKESHVIDW-UHFFFAOYSA-N 2,4-dichloro-n-[3,5-dichloro-4-[1-(4-fluorophenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=CC(F)=CC=C1N1N=CC(OC=2C(=CC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)Cl)=CC=2Cl)Cl)=C1 SRTYGDKESHVIDW-UHFFFAOYSA-N 0.000 claims 1
- VUMXMNSMRKKMHP-UHFFFAOYSA-N 2,4-dichloro-n-[3-chloro-4-(1-phenylpyrazol-4-yl)oxyphenyl]benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC=C1OC1=CN(C=2C=CC=CC=2)N=C1 VUMXMNSMRKKMHP-UHFFFAOYSA-N 0.000 claims 1
- VUJJFVJGSMWVQI-UHFFFAOYSA-N 2,4-dichloro-n-[3-chloro-4-[1-(3-chloro-4-fluorophenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=C(Cl)C(F)=CC=C1N1N=CC(OC=2C(=CC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)Cl)=C1 VUJJFVJGSMWVQI-UHFFFAOYSA-N 0.000 claims 1
- OKWDMAOYYKJBAG-UHFFFAOYSA-N 2,4-dichloro-n-[3-chloro-4-[1-(4-chlorophenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=CC(Cl)=CC=C1N1N=CC(OC=2C(=CC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)Cl)=C1 OKWDMAOYYKJBAG-UHFFFAOYSA-N 0.000 claims 1
- YQNUQKNPTKLBTP-UHFFFAOYSA-N 2,4-dichloro-n-[3-chloro-4-[1-(4-fluorophenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=CC(F)=CC=C1N1N=CC(OC=2C(=CC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)Cl)=C1 YQNUQKNPTKLBTP-UHFFFAOYSA-N 0.000 claims 1
- HMXIKIRJYFBFGS-UHFFFAOYSA-N 2,4-dichloro-n-[3-chloro-4-[1-[4-chloro-3-(trifluoromethyl)phenyl]pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(N2N=CC(OC=3C(=CC(NS(=O)(=O)C=4C(=CC(Cl)=CC=4)Cl)=CC=3)Cl)=C2)=C1 HMXIKIRJYFBFGS-UHFFFAOYSA-N 0.000 claims 1
- PHRGUKNKYADIRQ-UHFFFAOYSA-N 2,4-dichloro-n-[4-[1-(2,4-dimethylphenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC=C1N1N=CC(OC=2C=CC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)=C1 PHRGUKNKYADIRQ-UHFFFAOYSA-N 0.000 claims 1
- JELMMHQUJBCEFV-UHFFFAOYSA-N 2,4-dichloro-n-[4-[1-(4-fluorophenyl)pyrazol-4-yl]oxy-3-methylphenyl]benzenesulfonamide Chemical compound C=1C=C(OC2=CN(N=C2)C=2C=CC(F)=CC=2)C(C)=CC=1NS(=O)(=O)C1=CC=C(Cl)C=C1Cl JELMMHQUJBCEFV-UHFFFAOYSA-N 0.000 claims 1
- OBYQLZIZMCUOKI-UHFFFAOYSA-N 2,4-dichloro-n-[4-[1-(4-methylphenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1N1N=CC(OC=2C=CC(NS(=O)(=O)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)=C1 OBYQLZIZMCUOKI-UHFFFAOYSA-N 0.000 claims 1
- GEXAESDBMVFTNM-UHFFFAOYSA-N 4-methyl-n-[4-[1-(4-methylphenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1N1N=CC(OC=2C=CC(NS(=O)(=O)C=3C=CC(C)=CC=3)=CC=2)=C1 GEXAESDBMVFTNM-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- KVFYJVSRMJRCOI-UHFFFAOYSA-N n-[3-chloro-4-[1-(2,4-dimethylphenyl)pyrazol-4-yl]oxyphenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC=C1OC1=CN(C=2C(=CC(C)=CC=2)C)N=C1 KVFYJVSRMJRCOI-UHFFFAOYSA-N 0.000 claims 1
- ZRFYKRVSXGCZNF-UHFFFAOYSA-N n-[3-chloro-4-[1-(4-fluorophenyl)pyrazol-4-yl]oxyphenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC=C1OC1=CN(C=2C=CC(F)=CC=2)N=C1 ZRFYKRVSXGCZNF-UHFFFAOYSA-N 0.000 claims 1
- CMPDCTMUOOYJLD-UHFFFAOYSA-N n-[3-chloro-4-[1-(4-fluorophenyl)pyrazol-4-yl]oxyphenyl]benzenesulfonamide Chemical compound C1=CC(F)=CC=C1N1N=CC(OC=2C(=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=2)Cl)=C1 CMPDCTMUOOYJLD-UHFFFAOYSA-N 0.000 claims 1
- NYKRYHZIBMQASX-UHFFFAOYSA-N n-[4-[1-(2,4-dimethylphenyl)pyrazol-4-yl]oxyphenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C=C1)=CC=C1OC1=CN(C=2C(=CC(C)=CC=2)C)N=C1 NYKRYHZIBMQASX-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Spoj sa formulom (I) ili njegova farmaceutski prihvatljiva sol
[image]
naznačen time da,
R1, R2 ili R3 svaki neovisno predstavljaju halo, cijano, nitro, amino, alkil, haloalkil, alkoksi, haloalkoksi, karboksilnu kiselinu, CONH2, CONHMe, CONMe2, CONHEt, CONEt2, CONHPh, CON(OMe)Me, COOR" gdje R" predstavlja alkil ili fenilalkil;
R4 predstavlja vodik ili alkil;
m, n ili p neovisno predstavljaju 0, 1, 2 ili 3; te
izraz "alkil" uključuje oboje razgranate i ravnolančane zasićene ili nezasićene alifatske skupine ugljikovodika koje imaju 1 do 10 atoma ugljika.
2. Spoj prema zahtjevu 1, naznačen time da svaki R1, R2 i R3 koji se nalazi u spoju je neovisno odabran od metila, fluoro, kloro, trifluorometila, metoksi, i trifluorometoksi.
3. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da m, n, i p su neovisno 0, 1 ili 2.
4. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da m je 0, 1 ili 2.
5. Spoj prema zahtjevu 1 naznačen time da je odabran iz skupine koja sadrži:
2,4-Dikloro-N-[4-(1-p-tolil-1H-pirazol-4-iloksi)-fenil]-benzensulfonamid;
2,4-Dikloro-N-{3-kloro-4-[1-(4-kloro-3-trifluorometil-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
2,4-Dikloro-N-{3,5-dikloro-4-[1-(2,4-difluoro-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
2,4-Dikloro-N-{3,5-dikloro-4-[1-(4-fluoro-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
2,4-Dikloro-N-{3-kloro-4-[1-(4-fluoro-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
2,4-Dikloro-N-{3-kloro-4-[1-(4-kloro-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
2,4-Dikloro-N-{3-kloro-4-[1-(3-kloro-4-fluoro-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
N-{3-Kloro-4-[1-(4-fluoro-fenil)-1H-pirazol-4-iloksi]-fenil}-4-metil-benzensulfonamid;
2,4-Dikloro-N-{4-[1-(4-fluoro-fenil)-1H-pirazol-4-iloksi]-3-metil-fenil}-benzensulfonamid;
2,4-Dikloro-N-{4-[1-(2,4-dimetil-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
4-Metil-N-[4-(1-p-tolil-1H-pirazol-4-iloksi)-fenil]-benzensulfonamid;
N-{3-Kloro-4-[1-(4-fluoro-fenil)-1H-pirazol-4-iloksi]-fenil}-benzensulfonamid;
2,4-Dikloro-N-[3-kloro-4-(1-fenil-1H-pirazol-4-iloksi)-fenil]-benzensulfonamid;
N-{4-[1-(2,4-Dimetil-fenil)-1H-pirazol-4-iloksi]-fenil}-4-metil-benzensulfonamid; i
N-{3-Kloro-4-[1-(2,4-dimetil-fenil)-1H-pirazol-4-iloksi]-fenil}-4-metil-benzensulfonamid;
i njihove farmaceutski prihvatljive soli.
6. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem zahtjevu od 1-5 i jedan ili više farmaceutski prihvatljivih nosača ili pomoćnih tvari.
7. Farmaceutski pripravak prema zahtjevu 6 naznačen time da je prilagođen za davanje inhalacijom kroz nos ili usta.
8. Spoj prema bilo kojem zahtjevu od 1-5 naznačen time da je za upotrebu kod liječenja respiratorne bolesti.
9. Spoj prema zahtjevu 8, naznačen time da se spoj daje inhalacijom kroz nos ili usta.
10. Spoj prema zahtjevu 8 ili 9, naznačen time da je respiratorna bolest odabrana od astme, kronične opstruktivne plućne bolesti (KOPB), alergijskog sindroma dišnih putova, bronhitisa, cistične fibroze i emfizema.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3324CH2008 | 2008-12-30 | ||
| PCT/GB2009/002951 WO2010076553A1 (en) | 2008-12-30 | 2009-12-23 | Sulfonamide compounds for the treatment of respiratory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140022T1 true HRP20140022T1 (hr) | 2014-02-14 |
Family
ID=41600475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140022AT HRP20140022T1 (hr) | 2008-12-30 | 2014-01-08 | Spojevi sulfonamida za lijeäśenje respiratornih poremeä†aja |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8362064B2 (hr) |
| EP (1) | EP2379507B1 (hr) |
| JP (1) | JP5555255B2 (hr) |
| CN (1) | CN102272104B (hr) |
| AU (1) | AU2009334597B2 (hr) |
| BR (1) | BRPI0923862A2 (hr) |
| CA (1) | CA2748331C (hr) |
| CY (1) | CY1114798T1 (hr) |
| DK (1) | DK2379507T3 (hr) |
| EA (1) | EA019441B1 (hr) |
| ES (1) | ES2442343T3 (hr) |
| HK (1) | HK1158626A1 (hr) |
| HR (1) | HRP20140022T1 (hr) |
| MX (1) | MX2011007036A (hr) |
| NZ (1) | NZ594157A (hr) |
| PL (1) | PL2379507T3 (hr) |
| PT (1) | PT2379507E (hr) |
| SG (1) | SG172444A1 (hr) |
| SI (1) | SI2379507T1 (hr) |
| SM (1) | SMT201300156B (hr) |
| WO (1) | WO2010076553A1 (hr) |
| ZA (1) | ZA201104663B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10310294B2 (en) | 2012-07-24 | 2019-06-04 | Johnson & Johnson Vision Care, Inc. | Thinned and flexible semiconductor elements on three dimensional surfaces |
| EP2868706A1 (en) | 2013-10-29 | 2015-05-06 | DyStar Colours Distribution GmbH | Metal free acid dyes, methods for the production thereof and their use |
| US11008339B2 (en) | 2015-05-18 | 2021-05-18 | Shenyang Sinochem Agrochemicals R&D Co., Ltd. | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| JPH0525045A (ja) | 1991-07-18 | 1993-02-02 | Tanabe Seiyaku Co Ltd | 経皮吸収製剤 |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| AU759255B2 (en) * | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| SI20116A (sl) | 1998-12-02 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nov postopek za pripravo simvastatina in njegovih analogov |
| US6204288B1 (en) | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| GB9908647D0 (en) | 1999-04-15 | 1999-06-09 | Smithkline Beecham Plc | Novel compounds |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| EE200200602A (et) | 2000-04-27 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pikatoimelised beetamimeetikumid, meetod nende valmistamiseks ja nende kasutamine ravimitena |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| DE10346940B3 (de) | 2003-10-06 | 2005-06-16 | Schering Ag | Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
| SK287576B6 (sk) | 2000-08-05 | 2011-03-04 | Glaxo Group Limited | S-fluórmetylester kyseliny 6alfa, 9alfa-difluór-17alfa-[(2- furanylkarboxyl)oxy]-11beta-hydroxy-16alfa-metyl-3-oxo-androsta- 1,4-dién-17beta-karbotiovej, spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahom, jeho použitie a medziprodukty |
| AU2001288271A1 (en) | 2000-08-17 | 2002-02-25 | Harrihar A. Pershadsingh | Methods for treating inflammatory diseases |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| WO2002076933A1 (en) | 2001-03-22 | 2002-10-03 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| AR033290A1 (es) | 2001-04-30 | 2003-12-10 | Glaxo Group Ltd | Derivados antiinflamatorios de androstano |
| WO2002100879A1 (en) | 2001-06-12 | 2002-12-19 | Glaxo Group Limited | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| WO2003042229A1 (en) | 2001-11-12 | 2003-05-22 | Glaxo Group Limited | Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| AU2003222841A1 (en) | 2002-04-25 | 2003-11-10 | Glaxo Group Limited | Phenethanolamine derivatives |
| JP2005527618A (ja) | 2002-05-28 | 2005-09-15 | セラヴァンス インコーポレーテッド | アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| EP1556034B1 (en) | 2002-10-11 | 2008-04-16 | Pfizer Limited | Indole derivatives as beta-2 agonists |
| US20060205790A1 (en) | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| JP2006503888A (ja) | 2002-10-28 | 2006-02-02 | グラクソ グループ リミテッド | 呼吸器疾患を治療するためのフェネタノールアミン誘導体 |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| DE10258695A1 (de) | 2002-12-16 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel |
| CA2512987C (en) | 2003-01-21 | 2011-06-14 | Merck & Co., Inc. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| WO2004089892A2 (en) | 2003-04-01 | 2004-10-21 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity |
| BRPI0409198A (pt) | 2003-04-04 | 2006-05-02 | Novartis Ag | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas |
| EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| ATE435862T1 (de) | 2003-05-28 | 2009-07-15 | Theravance Inc | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| ATE384697T1 (de) | 2003-06-04 | 2008-02-15 | Pfizer | 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten |
| BRPI0412231A (pt) | 2003-07-01 | 2006-08-22 | Schering Ag | derivados de pentanol substituìdos heterociclicamente, processos para a sua preparação e sua aplicação como inibidores de inflamação |
| CN100482649C (zh) * | 2003-09-17 | 2009-04-29 | 诺瓦提斯公司 | 有机化合物 |
| WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| DE10347385A1 (de) | 2003-10-08 | 2005-05-12 | Schering Ag | Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| DE502004002403D1 (de) | 2003-10-08 | 2007-02-01 | Schering Ag | Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer |
| GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0328490D0 (en) | 2003-12-09 | 2004-01-14 | Glaxo Group Ltd | Medicinal compounds |
| GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
| US8070937B2 (en) | 2003-12-19 | 2011-12-06 | Shell Oil Company | Systems, methods, and catalysts for producing a crude product |
| DE102004001413A1 (de) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| GEP20084452B (en) | 2004-01-22 | 2008-08-10 | Pfizer | Sulfonamide derivatives for the treatment of diseases |
| DE602005002930T2 (de) | 2004-01-22 | 2008-07-24 | Pfizer Inc. | Sulfonamidderivate zur behandlung von krankheiten |
| DE102004003428A1 (de) | 2004-01-23 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel |
| ES2349470T3 (es) | 2004-02-14 | 2011-01-03 | Boehringer Ingelheim International Gmbh | Nuevos beta-2-agonistas de acción de larga duración y su utilización como medicamentos. |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| EP1577306A1 (de) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| EP1577292A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylaminoethanol derivatives as beta2 receptor agonists |
| HN2004000023A (es) | 2004-03-22 | 2007-11-23 | Mars Inc | Mascadura para animales |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| WO2005092860A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| ATE432278T1 (de) | 2004-03-23 | 2009-06-15 | Pfizer | Verbindungen zur behandlung von krankheiten |
| EP1730103B1 (en) | 2004-03-23 | 2010-05-26 | Pfizer Limited | Formamide derivatives useful as adrenoceptor |
| WO2005110990A1 (de) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
| EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
| DE102004024451A1 (de) | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
| DE102004024454A1 (de) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2569395A1 (en) | 2004-06-03 | 2005-12-22 | Theravance, Inc. | Diamine .beta.2 adrenergic receptor agonists |
| WO2006014704A1 (en) | 2004-07-21 | 2006-02-09 | Theravance, Inc. | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS |
| WO2006016245A1 (en) | 2004-08-05 | 2006-02-16 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006031556A2 (en) | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| WO2006051373A1 (en) | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
-
2009
- 2009-12-23 EA EA201101014A patent/EA019441B1/ru not_active IP Right Cessation
- 2009-12-23 SI SI200930823T patent/SI2379507T1/sl unknown
- 2009-12-23 NZ NZ594157A patent/NZ594157A/xx not_active IP Right Cessation
- 2009-12-23 PL PL09796030T patent/PL2379507T3/pl unknown
- 2009-12-23 AU AU2009334597A patent/AU2009334597B2/en not_active Ceased
- 2009-12-23 MX MX2011007036A patent/MX2011007036A/es active IP Right Grant
- 2009-12-23 SG SG2011048154A patent/SG172444A1/en unknown
- 2009-12-23 EP EP09796030.6A patent/EP2379507B1/en active Active
- 2009-12-23 US US13/142,697 patent/US8362064B2/en not_active Expired - Fee Related
- 2009-12-23 CA CA2748331A patent/CA2748331C/en not_active Expired - Fee Related
- 2009-12-23 ES ES09796030.6T patent/ES2442343T3/es active Active
- 2009-12-23 JP JP2011544077A patent/JP5555255B2/ja not_active Expired - Fee Related
- 2009-12-23 BR BRPI0923862-0A patent/BRPI0923862A2/pt not_active IP Right Cessation
- 2009-12-23 WO PCT/GB2009/002951 patent/WO2010076553A1/en active Application Filing
- 2009-12-23 DK DK09796030.6T patent/DK2379507T3/da active
- 2009-12-23 PT PT97960306T patent/PT2379507E/pt unknown
- 2009-12-23 CN CN200980153388.6A patent/CN102272104B/zh not_active Expired - Fee Related
-
2011
- 2011-06-23 ZA ZA2011/04663A patent/ZA201104663B/en unknown
- 2011-11-28 HK HK11112890.3A patent/HK1158626A1/xx not_active IP Right Cessation
-
2013
- 2013-12-19 SM SM201300156T patent/SMT201300156B/xx unknown
- 2013-12-27 CY CY20131101170T patent/CY1114798T1/el unknown
-
2014
- 2014-01-08 HR HRP20140022AT patent/HRP20140022T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0923862A2 (pt) | 2015-07-28 |
| NZ594157A (en) | 2013-07-26 |
| DK2379507T3 (da) | 2014-01-27 |
| EA019441B1 (ru) | 2014-03-31 |
| MX2011007036A (es) | 2011-07-20 |
| JP2012514027A (ja) | 2012-06-21 |
| WO2010076553A1 (en) | 2010-07-08 |
| CN102272104B (zh) | 2014-07-09 |
| EA201101014A1 (ru) | 2012-01-30 |
| EP2379507B1 (en) | 2013-10-16 |
| CY1114798T1 (el) | 2016-12-14 |
| HK1158626A1 (en) | 2012-07-20 |
| CA2748331C (en) | 2016-08-02 |
| ES2442343T3 (es) | 2014-02-11 |
| ZA201104663B (en) | 2012-10-31 |
| PT2379507E (pt) | 2014-01-21 |
| US8362064B2 (en) | 2013-01-29 |
| JP5555255B2 (ja) | 2014-07-23 |
| US20120041043A1 (en) | 2012-02-16 |
| EP2379507A1 (en) | 2011-10-26 |
| AU2009334597A1 (en) | 2011-07-21 |
| CA2748331A1 (en) | 2010-07-08 |
| CN102272104A (zh) | 2011-12-07 |
| SMT201300156B (it) | 2014-03-07 |
| SI2379507T1 (sl) | 2014-02-28 |
| PL2379507T3 (pl) | 2014-03-31 |
| AU2009334597B2 (en) | 2015-07-16 |
| SG172444A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140022T1 (hr) | Spojevi sulfonamida za lijeäśenje respiratornih poremeä†aja | |
| CO6310968A2 (es) | Derivados de 3,5-diamino sustituido-n-tetrahidropirimidin/imidazolin/diazepam-2-ilidenpirazin-2-carboxamida, utiles como bloqueadores de la actividad del canal de sodio epitelial (enac) | |
| ECSP10010336A (es) | Derivados de piridina | |
| CY1116994T1 (el) | 3,5-διαμινο-6-χλωρο-ν-(ν-(4-(4-(2-(εξυλ (2,3,4,5,6-πενταϋδροξυεξυλ) amino) αιθοξυ) φαινυλ) βουτυλ) καρβαμιμιδοϋλ) πυραζινο-2-καρβοξαμιδιο | |
| HRP20100020T1 (hr) | Novi derivati hidantoina za liječenje opstruktivnih bolesti dišnih putova | |
| HRP20100670T1 (hr) | Aril-supstituirani pirazol-amid spojevi korisni kao inhibitori kinaze | |
| HRP20080311T3 (hr) | Derivati pirazola, pripravci koji sadrže takve spojeve i postupci za njihovu primjenu | |
| TW200604198A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| JP2016500111A5 (hr) | ||
| HRP20210336T1 (hr) | Kristalni oblik inhibitora pde4 | |
| HRP20170307T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA | |
| HRP20200661T1 (hr) | Razine ceramida u liječenju i prevenciji infekcija | |
| JP2011201907A5 (hr) | ||
| RS52946B (en) | AMINOTETRAHYDROPIRATED AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| AR062104A1 (es) | Derivados de quinuclidina como antagonistas de m3 | |
| HRP20171614T1 (hr) | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju | |
| BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| CY1111133T1 (el) | Υπερλεπτο σκευασμα φορμοτερολης | |
| MD4425C1 (ro) | Alcoxipirazoli în calitate de activatori ai guanilat-ciclazei solubile | |
| RU2014127143A (ru) | Пиперидинил нафтилуксусные кислоты | |
| MX2020005738A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы | |
| HRP20191339T1 (hr) | Novi anelirani fenoksiacetamidi | |
| BR112014001369A2 (pt) | derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral | |
| EA200701879A1 (ru) | Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина |